English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Data for patients with bone metastases (BMs) of differentiated thyroid carcinoma (DTC) were retrospectively studied to identify factors associated with survival. We especially studied the impact of therapies. Among the 1977 patients followed for DTC in our department from 1958 to 1999, 109 (77 females and 32 males; age range, 20–87 yr) presented BMs. All patients except 1 underwent total thyroidectomy, followed by radioiodine therapy (≥3.7 gigabecquerels) in 95 cases. Survival rates at 5 and 10 yr were 41% and 15%, respectively. Univariate analyses indicated that a young age at BM discovery (P &amp;lt; 0.005) and the discovery of BM as a revealing symptom of DTC (P &amp;lt; 0.05) were features significantly associated with improved survival as well as radioiodine therapy (P &amp;lt; 10−4) and BM complete surgery (P &amp;lt; 0.02). Using multivariate analysis, the detection of BMs as a revealing symptom of thyroid carcinoma (P &amp;lt; 0.0005), the absence of metastasis appearance in other organs than bones during the follow-up (P &amp;lt; 0.03), the cumulative dose of radioiodine therapy (P &amp;lt; 0.0001), and complete BM surgery in young patients (P &amp;lt; 0.04) appeared as independent prognostic features associated with an improved survival.

Survival and Therapeutic Modalities in Patients with Bone Metastases of Differentiated Thyroid Carcinomas